115 results
Page 3 of 6
6-K/A
EX-99.1
e11hbg swmlj6dg
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.1
qfi8xf9hso7c76g
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
gcolkoqtjhi9ruvip
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
osc3z5nfxwvushn33f7
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.2
3zqf1pb28x830 650i
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.1
fmbi5e
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
zpdgy
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.2
8ruyj4uo
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.3
wuxl29
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
bg75fc52cwfj9i5
31 Mar 21
Current report (foreign)
7:15am
424B5
ea411 nvzmn0
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
cdm 4whp8a2d8
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-99.2
8hgps5lr
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.1
76ma2dinybc
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K/A
EX-99.1
g4bjv6 6up4
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
je6nm5att65c
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
681fwl4oklf
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
fs6w5
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
2np3qx8
10 Dec 20
Current report (foreign)
6:03am